- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04299243
Clinical Trial Protocol for Safety and Efficacy of Soft Contact Lens
Clinical Trial Protocol for Safety and Efficacy of Soft Contact Lens (Model: Spherical Lens)
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tianjin, China
- TianJin eye hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female with age of 18 to 45
- Spherical power: -0.25 to -10.00D
- Cylinder power ≤0.75D and Sph.P:Cyl.P≥3:1, or 1.00D≤ cylinder power ≤1.50D and Sph.P:Cyl.P ≥4:1;
Both eyes are ametropia, and there is no case where the investigator believes that the soft contact lens cannot be worn;
: The case of wearing a soft contact lens as referred to in this trial is: i) No eyelid abnormalities or infections; ii) No clinically significant slit lamp findings iii) No other active eye diseases.
- BCVA of the left and right eye subjective refraction is greater than or equal to 5.0.
Exclusion Criteria:
- Need to use therapeutic ophthalmic drugs, including antibiotics, hormones and compound ophthalmic drugs containing hormones
- Dry eye syndrome
- Any systemic disease contraindications to contact lenses or disease medications can affect the wearing of contact lenses
- Wearing a hard contact lens in the past 6 weeks
- Tear film break-up time is less than or equal to 5s
- Allergic to contact lenses and/or contact lenses
- Keratoconus or other irregular corneal patients
- Soft hydrophilic contact lens wearers are affected by long-term special conditions such as dryness, severe dust or volatile chemicals
- Pregnant, lactating or plan to be pregnant
- Only one eye meets the requirements for enrollment
- Participating in other clinical trials or less than ten days after the end of a soft contact lens clinical trial
- Less than three months after the end of a drug clinical trial
- Determined by the investigator that could not be enrolled
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Spherical Lens
Randomized to Spherical Lens worn in a daily disposable mode
|
Contact lenses for vision correction
|
Active Comparator: SiHy Daily
Randomized to SiHy Daily worn in a daily disposable mode
|
Contact lenses for vision correction
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The ratio of corrected visual acuity of left and right eyes is ≥5.0
Time Frame: 1 week
|
The standard logarithmic visual acuity chart consistent with the guiding principle is adopted in this scheme. - Success criteria: If the lower limit of 95% CI of the evaluated rate of corrected for visual acuity for both eyes ≥ 5.0 at 1 week visit is ≥-10%, the primary endpoint of the two groups is non-inferior. |
1 week
|
The occurrence of adverse events
Time Frame: 3 month
|
Compare the number of adverse events and serious adverse events, the number of cases and the incidence rate; list the number and cases of adverse events; describe the adverse events that are related to the investigational products.
|
3 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BCVA (spectacles) and BCVA (CL)
Time Frame: 1 week, 1 month, 3 months
|
BCVA (spectacles and CL) of both eyes are compared at baseline and at each follow-up.
|
1 week, 1 month, 3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Li Lihua, MD, TianJin eye hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SLP-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myopia
-
He Eye HospitalNot yet recruiting
-
University of BradfordCoopervision, Inc.; University of HuddersfieldNot yet recruiting
-
Visioneering Technologies, IncRecruitingMyopiaUnited States, Canada, Hong Kong, Singapore
-
University Eye Hospital, FreiburgRecruiting
-
Shanghai 10th People's HospitalCompletedMyopia | Myopia, ProgressiveChina
-
Tianjin Eye HospitalActive, not recruiting
-
Tianjin Eye HospitalCompleted
-
Sultan Qaboos UniversityChristian Medical College, Vellore, IndiaUnknown
-
Peking University People's HospitalUnknownProgressive MyopiaChina
-
Shanghai Eye Disease Prevention and Treatment CenterNot yet recruiting
Clinical Trials on Contact Lenses
-
Aller, Thomas A., ODJohnson & Johnson Vision Care, Inc.CompletedMyopia | Esophoria | Fixation Disparity
-
University of BradfordCoopervision, Inc.; University of HuddersfieldNot yet recruiting
-
Visioneering Technologies, IncRecruitingMyopiaUnited States, Canada, Hong Kong, Singapore
-
Coopervision, Inc.Completed
-
University of HoustonCompleted
-
Aston UniversityCollege of OptometristsCompletedHyperopia | Amblyopia | AnisohyperopiaUnited Kingdom
-
Johnson & Johnson Vision Care, Inc.CompletedContact Lens Base Curve (BC) Fit and ComfortUnited States
-
Coopervision, Inc.Completed
-
Ohio State UniversityActive, not recruiting
-
Alcon ResearchCompletedRefractive ErrorsUnited States